12:00 AM
 | 
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Stelara ustekinumab regulatory update

Johnson & Johnson submitted an sBLA to FDA and a Type II variation to EMA to expand the label of Stelara ustekinumab to include treatment of active...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >